© 2022 MJH Life Sciences and Cancer Network. All rights reserved.
© 2022 MJH Life Sciences™ and Cancer Network. All rights reserved.
Recommendations for treating patients with steroid-refractory chronic GVHD based on evidence demonstrated by the REACH3 trial.
October 29th 2021
Experts discuss differences between the clinical manifestations and symptoms of acute and chronic graft-vs-host disease.
Experts hold a discussion regarding the timing and onset of acute graft-vs-host disease and chronic graft-vs-host disease following allogeneic transplantation, and prophylactic strategies used to help protect patients.
November 5th 2021
Recommendations to help clinicians educate patients and caregivers about the risk of graft-vs-host disease following allogeneic transplantation.
A discussion on staging and grading criteria used in the assessment of acute graft-vs-host disease, and the potential role of biomarkers moving forward.
November 12th 2021
A panel of clinicians review the case of a patient with acute graft-vs-host disease and share how they typically approach similar scenarios.
Clinicians discuss how they treat patients with steroid-refractory acute graft-vs-host disease and consider where ruxolitinib fits into the therapeutic landscape.
Risk factors associated with chronic graft-vs-host disease, and insight regarding how the condition commonly presents in patients.
Resources that can help educate patients and community physicians about the risk for chronic graft-vs-host disease post-transplantation.
November 24th 2021
The best practices for treating patients with steroid-refractory chronic graft-vs-host disease, with implications for using ruxolitinib based on results of the REACH3 clinical trial.
Reactions to a case of chronic graft-vs-host disease and thoughts on sequencing therapy.